AnaptysBio (ANAB) Stock Price
AnaptysBio Price
Revenue has compounded at 36.8% per year over the past 12 years to 234.60 M USD. AnaptysBio's net margin stands at -5.6%, up from -91.5% several years earlier. Analysts set a median price target of 66.81 USD, implying 17.1% above the current price. Of 19 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 194% above its 52-week low.
AnaptysBio stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of AnaptysBio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AnaptysBio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AnaptysBio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | AnaptysBio Price |
|---|---|
| 8/31/2026 | 57.03 USD |
| 8/30/2026 | 56.56 USD |
| 8/28/2026 | 56.08 USD |
| 8/27/2026 | 57.60 USD |
| 8/26/2026 | 58.00 USD |
| 8/25/2026 | 58.37 USD |
| 8/24/2026 | 58.23 USD |
| 8/21/2026 | 57.74 USD |
| 8/20/2026 | 56.69 USD |
| 8/19/2026 | 58.80 USD |
| 8/18/2026 | 58.77 USD |
| 8/14/2026 | 58.47 USD |
| 8/13/2026 | 56.02 USD |
| 8/12/2026 | 57.37 USD |
| 8/10/2026 | 56.51 USD |
| 8/7/2026 | 56.61 USD |
| 8/6/2026 | 54.77 USD |
| 8/5/2026 | 55.17 USD |
| 8/4/2026 | 53.65 USD |
| 8/3/2026 | 53.66 USD |
| 7/31/2026 | 53.36 USD |
| 7/30/2026 | 55.04 USD |
| 7/29/2026 | 51.40 USD |
| 7/27/2026 | 54.65 USD |
| 7/23/2026 | 54.91 USD |
| 7/22/2026 | 52.61 USD |
| 7/21/2026 | 53.76 USD |
| 7/20/2026 | 50.29 USD |
| 7/17/2026 | 58.00 USD |
| 7/16/2026 | 54.15 USD |
AnaptysBio Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
AnaptysBio Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 15.00 | 17.00 | 16.00 | 10.00 | 5.00 | 8.00 | 75.00 | 63.00 | 10.00 | 17.00 | 91.00 | 234.00 | 94.00 | 148.00 |
| – | 200.00 | 13.33 | -5.88 | -37.50 | -50.00 | 60.00 | 837.50 | -16.00 | -84.13 | 70.00 | 435.29 | 157.14 | -59.83 | 57.45 |
| -60.00 | 46.67 | 1,364.71 | 6.25 | -190.00 | -1,020.00 | -1,137.50 | -6.67 | -55.56 | -780.00 | -676.47 | -79.12 | 99.15 | 99.15 | 99.15 |
| -3.00 | 7.00 | 232.00 | 1.00 | -19.00 | -51.00 | -91.00 | -5.00 | -35.00 | -78.00 | -115.00 | -72.00 | 232.00 | 93.20 | 146.74 |
| -5.00 | 4.00 | -3.00 | -3.00 | -29.00 | -66.00 | -107.00 | -23.00 | -57.00 | -115.00 | -164.00 | -114.00 | 47.00 | 19.00 | 91.00 |
| -100.00 | 26.67 | -17.65 | -18.75 | -290.00 | -1,320.00 | -1,337.50 | -30.67 | -90.48 | -1,150.00 | -964.71 | -125.27 | 20.09 | 20.21 | 61.49 |
| -5.00 | – | -5.00 | -4.00 | -30.00 | -61.00 | -97.00 | -19.00 | -57.00 | -128.00 | -163.00 | -145.00 | -13.00 | -13.00 | 125.00 |
| – | – | – | -20.00 | 650.00 | 103.33 | 59.02 | -80.41 | 200.00 | 124.56 | 27.34 | -11.04 | -91.03 | – | -1,061.54 |
| 8.00 | 2.48 | 2.62 | 2.65 | 23.09 | 26.79 | 27.15 | 27.94 | 27.53 | 28.45 | 26.59 | 30.45 | 31.34 | 31.34 | 31.34 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales AnaptysBio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AnaptysBio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AnaptysBio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares AnaptysBio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AnaptysBio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
AnaptysBio stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
AnaptysBio Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
AnaptysBio business model & stock analysis
AnaptysBio SWOT Analysis
Strengths
AnaptysBio Inc possesses several strengths that contribute to its success in the biotechnology industry. Firstly, the company has a strong and experienced management team with expertise in drug discovery and development. This enables them to make informed decisions and effectively navigate the complex regulatory landscape.
Secondly, AnaptysBio Inc boasts a robust portfolio of proprietary antibody therapeutics, which have shown promising results in preclinical and clinical trials. These innovative products have the potential to address unmet medical needs and generate significant revenue for the company.
Additionally, the company's strong financial position and access to capital provide them with the resources to further advance their research and development activities, and forge strategic partnerships with other industry leaders. This financial stability enables AnaptysBio Inc to pursue long-term growth and remain at the forefront of scientific advancements.
Weaknesses
Despite its strengths, AnaptysBio Inc also faces certain weaknesses that may hinder its performance. One notable weakness is its dependence on a limited number of proprietary antibody programs. This concentration of resources increases the company's vulnerability to setbacks, such as failed clinical trials or patent disputes.
Additionally, AnaptysBio Inc operates in a highly competitive industry, competing against larger pharmaceutical companies with substantial resources and established market presence. This competitive landscape puts pressure on the company to differentiate itself and successfully commercialize its products.
Opportunities
AnaptysBio Inc has several opportunities to capitalize on in the biotechnology sector. One major opportunity lies in the increasing demand for innovative antibody-based therapies. The growing prevalence of chronic diseases and the need for personalized medicine create a favorable market environment for AnaptysBio Inc to introduce and market their products.
Furthermore, the company can explore collaborations and licensing agreements with larger pharmaceutical companies to gain access to their established distribution networks and accelerate the commercialization of their products. This strategic approach can help penetrate new markets and broaden their revenue streams.
Threats
AnaptysBio Inc faces various threats that could impact its future prospects. One significant threat is the risk of regulatory hurdles and delays in obtaining necessary approvals for their drug candidates. The stringent regulatory requirements in the biopharmaceutical industry can prolong the time to market and increase costs.
Moreover, intellectual property disputes and patent challenges pose a threat to AnaptysBio Inc's market exclusivity and competitive advantage. Rival companies may challenge their patents, leading to lengthy legal battles that drain resources and potentially limit their market share.
AnaptysBio Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
AnaptysBio Segments
AnaptysBio Revenue by Segment
Max
Details
AnaptysBio Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
AnaptysBio historical P/E ratio, EBIT multiple, and P/S ratio
AnaptysBio annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
AnaptysBio shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current AnaptysBio forecasts and price targets in September 2026
Analyst Price Targets 2026AnaptysBio Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/13/2026 | Maintained | Buy | 46 | |
| 5/13/2026 | Maintained | Overweight | 57 | |
| 5/4/2026 | Maintained | Overweight | 50 | |
| 4/28/2026 | Maintained | Outperform | – | |
| 4/22/2026 | Maintained | Overweight | 57 | |
| 4/21/2026 | Maintained | Buy | 46 | |
| 3/31/2026 | Maintained | Overweight | 50 | |
| 3/30/2026 | Maintained | Buy | – | |
| 3/17/2026 | Maintained | Buy | 46 | |
| 3/12/2026 | Maintained | Outperform | 58 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
AnaptysBio Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/10/2026 | -0.07USD | - | 31.27 MUSD | - | 2026 Q2 |
| 5/7/2026 | -0.96USD | - | 29.12 MUSD | - | 2026 Q1 |
| 3/9/2026 | 0.96USD | - | 93.89 MUSD | - | 2025 Q4 |
| 11/7/2024 | -1.74USD | - | 7.01 MUSD | - | 2024 Q3 |
| 5/9/2024 | -1.67USD | - | 1.99 MUSD | - | 2024 Q1 |
| 2/28/2024 | -1.62USD | - | 2.35 MUSD | - | 2023 Q4 |
| 11/6/2023 | -1.13USD | - | 2.08 MUSD | - | 2023 Q3 |
| 8/7/2023 | -1.07USD | - | 1.78 MUSD | - | 2023 Q2 |
| 5/2/2023 | -1.04USD | - | 1.67 MUSD | - | 2023 Q1 |
| 3/6/2023 | -0.95USD | - | 6.12 MUSD | - | 2022 Q4 |
EESG©
Eulerpool ESG Scorecard© for the AnaptysBio stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
AnaptysBio shareholder structure
| % | Name |
|---|---|
27.40140% | |
27.40140% | |
6.72123% | |
5.84665% | |
5.36002% | |
5.18778% |
AnaptysBio Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.00% | SEC ↗ | |
10.51% | SEC ↗ | |
7.00% | SEC ↗ | |
6.80% | SEC ↗ | |
6.80% | SEC ↗ | |
6.70% | SEC ↗ | |
6.20% | SEC ↗ | |
5.80% | SEC ↗ | |
5.80% | SEC ↗ | |
5.80% | SEC ↗ |
AnaptysBio Executives and Management Board
12 members · avg. age 63 · 17 % women
Mr. Daniel Faga (45)
President, Chief Executive Officer, Director · since 2021
13.63 M USD
Management
Dr. Paul Lizzul (50)
Chief Medical Officer
Mr. Dennis Mulroy (70)
Chief Financial Officer
Mr. Eric Loumeau (62)
Chief Legal Officer
Board of Directors
Mr. John Orwin (63)
Non-Executive Independent Chairman of the Board
Dr. J. Anthony Ware (72)
Independent Director
Mr. John Schmid (62)
Independent Director
Dr. Dennis Fenton (73)
Independent Director
Dr. Magda Marquet (66)
Independent Director
Mr. Hollings Renton (78)
Independent Director
AnaptysBio Supply Chain
AnaptysBio Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.88 | -0.67 | -0.08 | ||
| 2 | -0.67 | -0.03 | 0.10 |
Frequently asked questions about AnaptysBio
The business model of AnaptysBio Inc is focused on discovering and developing novel antibody-based therapeutics for inflammation and immuno-oncology. With a strong emphasis on research and development, AnaptysBio utilizes its proprietary technology platform to generate highly specific therapeutic antibodies. These antibodies are aimed at targeting and modulating key immune system pathways to address various diseases, including inflammatory disorders, severe allergies, and certain types of cancers. By leveraging its expertise in antibody engineering and design, AnaptysBio aims to deliver innovative treatments that can improve patient outcomes and provide value to healthcare providers.
AnaptysBio Inc is primarily active in the biotechnology industry.
The main competitors of AnaptysBio Inc in the market are Regeneron Pharmaceuticals, Inc., Amgen Inc., and Novartis AG.
AnaptysBio Inc is a biotechnology company based in San Diego, California. Established in 2005, the company specializes in the discovery and development of therapeutic antibodies to address unmet medical needs. With a focus on inflammation, immuno-oncology, and rare diseases, AnaptysBio Inc utilizes its proprietary antibody discovery platform to identify and develop potential treatments. The company has forged collaborations with leading pharmaceutical companies and has a diverse pipeline of antibody candidates. AnaptysBio Inc's commitment to innovation and expertise in antibody-based therapies has positioned them as a prominent player in the biotech industry.
AnaptysBio Inc has achieved several significant milestones. The company has successfully developed novel antibody therapeutics for various severe diseases, including atopic dermatitis and peanut allergies. Additionally, AnaptysBio Inc has also entered into strategic collaborations with renowned pharmaceutical companies to further advance its drug pipeline. The company's dedication to research and development has led to the successful completion of multiple clinical trials, demonstrating their commitment to improving patient outcomes. With their innovative approach and strong partnerships, AnaptysBio Inc continues to pave the way in the field of biotechnology.
AnaptysBio Inc is primarily present in the United States.
AnaptysBio Inc represents a commitment to scientific innovation and excellence in the field of biotechnology. Its core values include a focus on discovering and developing novel antibody therapeutics to address unmet medical needs. The company strives to create value for patients, healthcare professionals, and shareholders through its cutting-edge research and development efforts. With a corporate philosophy centered around collaboration, AnaptysBio Inc aims to leverage its expertise and partnerships to drive forward breakthrough therapies that have the potential to improve patients' lives and revolutionize healthcare.
Analysts currently set an average price target of 65.87 USD for the AnaptysBio stock (median: 66.81 USD), implying +18.0 % versus the latest price. The consensus is based on 19 analyst ratings.
19 analysts currently rate the AnaptysBio stock: 17 recommend buying, 2 holding and 0 selling. For 2026, analysts expect AnaptysBio to generate revenue of 94.28 M USD and earnings per share of -0.43 USD.
Converted at the current exchange rate, the AnaptysBio share trades at 49.24 EUR (57.03 USD).
The AnaptysBio share (ANAB) is listed on 5 stock exchanges, including: NASDAQ (ANAB), Frankfurt (AN6.F), München (AN6.MU), Düsseldorf (AN6.DU), London (0HFQ.L).
AnaptysBio Inc is an innovative biotechnology company that focuses on the discovery and development of new biological therapeutics. The company was founded in 2005 in San Diego, California, and has since gained a leading position in the industry. The business model of AnaptysBio is based on the development of highly effective antibodies with a focus on inflammatory diseases and cancer. The scientists and developers at AnaptysBio use the latest technologies to identify and develop potential candidates in a rapid, precise, and cost-effective approach. AnaptysBio takes a differentiated approach to antibody identification and specializes in the development of biological therapeutics. AnaptysBio has a wide range of products, including Atrmab, ANB020, ANB019, and Etokimab. Atrmab is a nasal administration antibody product developed to treat allergic diseases such as hay fever. ANB020 is an antibody specifically targeting the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. On the other hand, the antibody ANB019 is being developed as a therapy option for both Generalized Pustular Psoriasis (GPP) and Palmoplantar Pustular Psoriasis (PPP). Etokimab, on the other hand, aims to treat tessin and chronic pruritus. This is a non-specific skin disease characterized by constant itching and tingling. By developing innovative therapies, AnaptysBio is able to achieve significant advancements in the field of biological medicines. These therapeutics will help improve the lives of patients in various stages of the disease. AnaptysBio benefits from serving a small but rapidly growing niche in the industry. There is a high demand for specialized biological medicines, as these medicines are often more effective and better tolerated than traditional medicines and are therefore preferred by many doctors. AnaptysBio finances its business activities through investment capital and strategic partnerships with large pharmaceutical companies. In the early stages of biological therapeutic development, AnaptysBio plays an important role by conducting proof-of-concept studies and demonstrating the potential of new therapeutics. Once the therapeutics move into clinical phases, pharmaceutical companies seek collaborations to conduct joint clinical trials and enter the market. Overall, AnaptysBio is a successful biotech company that is capable of revolutionizing therapy approaches for inflammatory and cancerous diseases. Through collaboration with large pharmaceutical companies and the development of innovative products, AnaptysBio is in a strong position to achieve further growth and success.
The expected revenue of AnaptysBio is 94.28 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of AnaptysBio is -13.44 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of AnaptysBio is currently -133.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AnaptysBio stock.
The price-to-sales ratio (P/S) of AnaptysBio is currently 18.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AnaptysBio stock.
The Eulerpool Quality Score for AnaptysBio is 6/10.
The ISIN of AnaptysBio is US0327241065. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of AnaptysBio is A2AJ8C. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of AnaptysBio is ANAB. The ticker symbol is used to trade AnaptysBio shares on the stock exchange.
AnaptysBio paid dividends every year for the past 0 years.
AnaptysBio is assigned to the 'Health' sector.
The dividends of AnaptysBio are distributed in USD.
AnaptysBio stock
AnaptysBio Peer Group
AnaptysBio Ticker
AnaptysBio FIGI
All fundamentals and in-depth analysis of AnaptysBio
Our stock analysis for AnaptysBio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnaptysBio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.